argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
560.90
+11.25 (2.05%)
At close: May 12, 2025, 4:00 PM
559.98
-0.92 (-0.16%)
After-hours: May 12, 2025, 4:03 PM EDT
argenx SE Revenue
argenx SE had revenue of $807.37M in the quarter ending March 31, 2025, with 95.72% growth. This brings the company's revenue in the last twelve months to $2.64B, up 82.13% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$2.64B
Revenue Growth
+82.13%
P/S Ratio
12.81
Revenue / Employee
$1,652,947
Employees
1,599
Market Cap
33.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARGX News
- 3 days ago - Argenx Q1 Earnings: Less Than Perfect Report Gets Punished - Seeking Alpha
- 3 days ago - argenx SE (ARGX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - argenx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 days ago - argenx to Present at BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 11 days ago - argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 - GlobeNewsWire
- 14 days ago - argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - GlobeNewsWire
- 4 weeks ago - FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting - Benzinga
- 4 weeks ago - argenx Announces Annual General Meeting of Shareholders on May 27, 2025 - GlobeNewsWire